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The articles in this issue cover a wide range oftopics but progress is a common theme. DrsAdams and Lichter make a strong case for
promoting meaningful interaction between research,
clinical practice and governmental policy on a global
scale. They focus on the National Cancer Act in the USA
and the recent United Nations historic High-level Meeting
on Noncommunicable Diseases (NCDs), only the second
of its kind, in which cancer features strongly as a growing
problem. It is a sad but arguably welcome irony that
while in the world at large infectious and cardiovascular
diseases are still the main natural premature killers, those
forms of progress that distinguish the ‘developing’ from
the ‘developed’  countries bring with them an increasing health
burden in the form of cancer.  
Both NCDs and infectious diseases are contributed to by lifestyle
and public health issues. In the case of infectious and parasitic
agents there is a perpetual battle with the causative or facilitating
organisms which adapt to overcome advances in medicine –
antibiotic resistance and species-crossing flu viruses being the most
high profile examples. I am not sure this is the case with NCDs and
with cancer in particular, although patterns of different cancer
incidences change and our metabolism has evolved a plethora of
alternative or ‘redundant’ pathways that can reduce the efficacy of
finely targeted therapies. There is, of course, overlap between
infectious diseases and cancer.  Any pathology that facilitates
mutagenesis through free radical formation confers a cancer risk.
Lifestyle and community health issues feature in minimising both
Cancer and NCDs. Dr Dwek’s group at Westminster University write
about diet and specifically the role of different forms of phytoestrogen
consumption in the progression of breast cancer.  The DietCompLyf
study finished recruiting earlier this year; the baseline conditions are
logged and the results of the follow-up are eagerly awaited.
Another link, between social, rather than nutritional lifestyle
influences and cancer is explored by Dr Fredrik Söderqvist. It
concerns the possibility of a risk of brain tumours, particularly
glioma, being induced by exposure to radiofrequency
electromagnetic fields. The link is currently relatively tenuous and
controversial but the importance of resolving the issue is enhanced
in that exposure due to the use of wireless phones is now
commonplace among quite young children and the levels of
exposure increasing and persisting throughout life. 
Dr Drake and colleagues review progress In the recognition of
Human Chorionic Gonadotrophin as a marker and conceivably a
therapeutic target In muscle invasive bladder cancer. They highlight,
among other things, fluctuating levels of interest and
research activity over time. Trends and fashion are
features of most human activity, often with good
underlying causes, in medicine commonly related to
technical innovations.
To complement articles exploring strategies for cancer
prevention, modulating its progression and the search for
new, better or additional markers and drug targets, there
is the description, by Ms Kamani and Mr De of
improvements in the most traditional of approaches to
cancer treatment: surgical excision. Minimally Invasive
Video Assisted Thyroidectomy (MIVAT) is described
potentially offering reduced trauma, better post-operative
course and improved cosmetic results resulting in enhanced patient
satisfaction. However, conventional surgery also gives excellent
results with less patient selection and well established low
complication rates. So the law of diminishing returns come into play
and the adoption of MIVAT depends, apart from considerations of
patient pressure, on the attitude of surgeons subjecting themselves to
a considerable learning curve for small advantages in outcome for a
minority of patients.
The MIVAT study is the article that most closely addresses limitations
to the advantages that can be derived as a result of progress; however,
it applies in all areas. Progress is an empty concept without a goal,
however remote. We are stuck with the certainty that total mortality
will continue indefinitely at 100%, excluding accidents and violence;
indeed this outcome is as desirable as it is inevitable. The goal has to
be to minimise suffering and to ensure an optimal lifespan for as many
as possible. This means targeting resources and coordinating effort
globally by governmental or supranational organisations. Quite what an
optimal lifespan should be may however be a very individual
assessment. We are already in an age where, at the margins of
healthcare and extreme stresses apply, a few people want and
aggressively press for some conceptual and practical input into their
exit strategy for life. Those organisations funding and directing research
and clinical services will ultimately need to pay increasing attention to
such issues, at least in terms of setting priorities.  Cancer research –
particularly studies aimed at prevention, early detection and developing
less onerous therapies - should hold up well in relation to infections
and other NCDs in the context of reducing suffering, as many of its
forms are debilitating and distressing.  I think that in my (imminent)
old age, I would prefer to be assisted preferentially to keep clear of
cancer and remain relatively happy to play Russian roulette with the
seasonal ‘flu virus mutant, leaving the development of ever more
sophisticated vaccines  as a benefit for the young.
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